Novo-Nordisk Value Stock - Dividend - Research Selection
Market price: 612,91 DKK
Novo-Nordisk A/S Fundamental data and company key figures of the share
|Annual reports in DKK|
|Net operating cash flow||51.951.000.000|
|Free cash flow||29.870.000.128|
|Liabilities & Shareholders equity||144.922.000.000|
|Diluted shares outstanding||2.340.000.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||207.321.628.672,00 USD|
|Indices||STOXX EUROPE 600,MSCI World Index|
|Raw Data Source||IFRS in Millionen DKK|
|Stock Split||2014-01-10,5.0000/1.0000; 2014-01-09,5.0000/1.0000; 2007-12-18,2.0000/1.0000; 2007-12-17,2.0000/1.0000; 2001-04-12,5.0000/2.0000; 2001-04-11,5.0000/2.0000; 1994-04-19,4.0000/1.0000; 1994-04-18,4.0000/1.0000|
Description of the company
Novo Nordisk A/S is a Denmark-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes care and Biopharmaceuticals. The Diabetes care division offers a range of diabetes products, including insulin pens and needles, such as FlexPen, NovoPen and FlexTouch, among others, and diabetes medicine, such as insulin- and non-insulin treatment, among others. The Biopharmaceuticals division provides products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas. As of December 31, 2012, the Company marketed its products in five reported geographical regions, namely North America, Europe, Region China, Japan and Korea, as well as International Operations. The Company wholly owns over 70 subsidiaries, such as Novo Nordisk Pharma GmbH, Novo Nordisk Canada Inc., Novo Nordisk Region Japan & Korea A/S, among others.